Drug profile · INN
baloxavir marboxil
XOFLUZA
baloxavir marboxil (XOFLUZA) is a polymerase acidic protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — baloxavir marboxil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
baloxavir marboxil (XOFLUZA) is a polymerase acidic protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Polymerase acidic protein inhibitor
Primary target: Polymerase acidic protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Congress & event coverage
- PresentationPharma Manufacturing World
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is baloxavir marboxil?
baloxavir marboxil (XOFLUZA) is a polymerase acidic protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for baloxavir marboxil?
XOFLUZA is a marketed brand name for baloxavir marboxil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of baloxavir marboxil?
baloxavir marboxil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.